U.S. Army Medical Research Institute of Infectious Diseases
Fort Deterick, Maryland, 21702, United States
NCT Number: NCT00584454
The purpose of this study is to evaluate the safety of Q Fever vaccine, NDBR 105, and collect data on incidence of occupational Q Fever infection in at risk personnel.
Looking for future studies?
Notify Me17 year–65 year
All sexes
Interventional
Phase 2
Fort Deterick, Maryland, 21702, United States
Study Objectives:
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Each volunteer will receive an intradermal dose of 0.1 ml of the skin test antigen (Q fever Skin Test Antigen, Henzerling Strain, Phase I, MNLBR 110) in the volar aspect of the arm on Day -7 of the study.Volunteers with skin test reactions that are considered negative may be vaccinated with Q Fever Vaccine, Phase I, Inactivated, Freeze-Dried, NDBR 105 (subcutaneously, 0.5 ml) in the upper outer aspect of the arm on Day 0 of the study.
Time frame: AEs recorded through day 28 after vaccination; SAEs recorded through duration of study; Confirmed occupational illness recorded through duration of study
Observe adverse reactions and occupational illness endpoint measurements 7 days follow-up after receipt of skin test antigen and 12 months of follow-up after receipt of vaccine
U.S. Army Medical Research and Development Command
Fed
Continued Evaluation of the Safety of Q Fever Vaccine, Phase I, Inactivated, Freeze Dried, NDBR 105, in Those at Risk of Exposure to Coxiella Burnetii, A Phase 2 Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02822807
Auto-Immunity, Bacterial Infections
Marseille, France
View Trial DetailsNCT01318356
Bacterial Infections, Bacterial Infections and Mycoses
Nijmegen, Gelderland, Netherlands
View Trial DetailsNCT02898402
Bacterial Infections, Bacterial Infections and Mycoses
View Trial DetailsNCT07358910
Adenophorea Infections, Adenoviridae Infections
Phnom Penh, Cambodia
View Trial Details